FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139304883> ?p ?o ?g. }

• W3139304883 endingPage "175883592199858" @default.
• W3139304883 startingPage "175883592199858" @default.
• W3139304883 abstract "Androgen deprivation therapy (ADT) is the foundation of treatment for patients with locally advanced, recurrent and metastatic prostate cancer, most commonly using luteinizing releasing hormone (LHRH) agonists. More recently, a new approach to ADT has emerged with the development of gonadotropin-releasing hormone (GnRH) antagonists, which aim to overcome some of the potential adverse physiologic effects of LHRH agonists. This article focuses on the newest GnRH antagonist, relugolix – a once-daily treatment and the only oral GnRH antagonist that has now been approved for the treatment of advanced prostate cancer. In phase II and III studies, relugolix achieved rapid and sustained castration without the testosterone surge associated with LHRH agonists, thus avoiding the potential clinical consequences of tumor flare and the necessity for concomitant anti-androgen therapy. Relugolix also achieved rapid testosterone recovery, which may potentially reduce ADT-related adverse events and offer opportunities for combination and intermittent therapy strategies. Cardiovascular safety is a particular concern in men with prostate cancer and ADT further increases cardiovascular risk: indeed, LHRH agonists are required to have a drug label warning about an increased risk of cardiovascular disease. Data from the phase III HERO study demonstrate an improved cardiac safety profile for the GnRH antagonist relugolix compared with the LHRH agonist leuprolide, including a significantly reduced risk for a major adverse cardiovascular event. Taken together, the data indicate that relugolix may mitigate some of the cardiovascular concerns surrounding ADT and has the potential to become a new standard of care for men with prostate cancer. In summary, relugolix represents a novel and recently available prostate cancer management strategy, incorporating the mechanistic advantages of GnRH antagonists and the potential benefits of oral administration." @default.
• W3139304883 created "2021-03-29" @default.
• W3139304883 creator A5053749991 @default.
• W3139304883 creator A5088518998 @default.
• W3139304883 date "2021-01-01" @default.
• W3139304883 modified "2023-10-17" @default.
• W3139304883 title "Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer" @default.
• W3139304883 cites W1555078472 @default.
• W3139304883 cites W1878336561 @default.
• W3139304883 cites W1933794219 @default.
• W3139304883 cites W1935718084 @default.
• W3139304883 cites W1964459692 @default.
• W3139304883 cites W1965647115 @default.
• W3139304883 cites W2005990105 @default.
• W3139304883 cites W2008203144 @default.
• W3139304883 cites W2016927496 @default.
• W3139304883 cites W2026353449 @default.
• W3139304883 cites W2030196700 @default.
• W3139304883 cites W2037021117 @default.
• W3139304883 cites W2044007006 @default.
• W3139304883 cites W2049161486 @default.
• W3139304883 cites W2091831668 @default.
• W3139304883 cites W2097930057 @default.
• W3139304883 cites W2099037568 @default.
• W3139304883 cites W2131170102 @default.
• W3139304883 cites W2327794806 @default.
• W3139304883 cites W2337137963 @default.
• W3139304883 cites W2509578420 @default.
• W3139304883 cites W2587863482 @default.
• W3139304883 cites W2590061441 @default.
• W3139304883 cites W2596675526 @default.
• W3139304883 cites W2753820779 @default.
• W3139304883 cites W2888204653 @default.
• W3139304883 cites W2949925748 @default.
• W3139304883 cites W2969494549 @default.
• W3139304883 cites W2978083517 @default.
• W3139304883 cites W2989626047 @default.
• W3139304883 cites W3013064839 @default.
• W3139304883 cites W3014348002 @default.
• W3139304883 cites W3020820143 @default.
• W3139304883 cites W3032046986 @default.
• W3139304883 doi "https://doi.org/10.1177/1758835921998586" @default.
• W3139304883 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8366106" @default.
• W3139304883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34408793" @default.
• W3139304883 hasPublicationYear "2021" @default.
• W3139304883 type Work @default.
• W3139304883 sameAs 3139304883 @default.
• W3139304883 citedByCount "5" @default.
• W3139304883 countsByYear W31393048832022 @default.
• W3139304883 countsByYear W31393048832023 @default.
• W3139304883 crossrefType "journal-article" @default.
• W3139304883 hasAuthorship W3139304883A5053749991 @default.
• W3139304883 hasAuthorship W3139304883A5088518998 @default.
• W3139304883 hasBestOaLocation W31393048831 @default.
• W3139304883 hasConcept C121608353 @default.
• W3139304883 hasConcept C126322002 @default.
• W3139304883 hasConcept C134018914 @default.
• W3139304883 hasConcept C143998085 @default.
• W3139304883 hasConcept C197934379 @default.
• W3139304883 hasConcept C2777899217 @default.
• W3139304883 hasConcept C2777911890 @default.
• W3139304883 hasConcept C2778575703 @default.
• W3139304883 hasConcept C2778894405 @default.
• W3139304883 hasConcept C2779279991 @default.
• W3139304883 hasConcept C2780192828 @default.
• W3139304883 hasConcept C2781114028 @default.
• W3139304883 hasConcept C71315377 @default.
• W3139304883 hasConcept C71924100 @default.
• W3139304883 hasConceptScore W3139304883C121608353 @default.
• W3139304883 hasConceptScore W3139304883C126322002 @default.
• W3139304883 hasConceptScore W3139304883C134018914 @default.
• W3139304883 hasConceptScore W3139304883C143998085 @default.
• W3139304883 hasConceptScore W3139304883C197934379 @default.
• W3139304883 hasConceptScore W3139304883C2777899217 @default.
• W3139304883 hasConceptScore W3139304883C2777911890 @default.
• W3139304883 hasConceptScore W3139304883C2778575703 @default.
• W3139304883 hasConceptScore W3139304883C2778894405 @default.
• W3139304883 hasConceptScore W3139304883C2779279991 @default.
• W3139304883 hasConceptScore W3139304883C2780192828 @default.
• W3139304883 hasConceptScore W3139304883C2781114028 @default.
• W3139304883 hasConceptScore W3139304883C71315377 @default.
• W3139304883 hasConceptScore W3139304883C71924100 @default.
• W3139304883 hasLocation W31393048831 @default.
• W3139304883 hasLocation W31393048832 @default.
• W3139304883 hasLocation W31393048833 @default.
• W3139304883 hasOpenAccess W3139304883 @default.
• W3139304883 hasPrimaryLocation W31393048831 @default.
• W3139304883 hasRelatedWork W1950049800 @default.
• W3139304883 hasRelatedWork W1979452793 @default.
• W3139304883 hasRelatedWork W1986311037 @default.
• W3139304883 hasRelatedWork W2012502375 @default.
• W3139304883 hasRelatedWork W2025304600 @default.
• W3139304883 hasRelatedWork W2030197842 @default.
• W3139304883 hasRelatedWork W2039222105 @default.
• W3139304883 hasRelatedWork W2061554880 @default.
• W3139304883 hasRelatedWork W2140787618 @default.
• W3139304883 hasRelatedWork W2397972377 @default.
• W3139304883 hasVolume "13" @default.

• next